Navigation Links
Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
Date:12/8/2013

New York, New York (PRWEB) December 08, 2013

The attorneys at Bernstein Liebhard LLP have launched a new website for individuals seeking to file NaturaLyte and GranuFlo lawsuit (http://www.dialysislawsuitclaims.com/) claims. Vital to anyone who may have suffered a stroke, heart attack, sudden cardiac death or another cardiovascular injury allegedly stemming from either of these dialysis medications, information about last year’s GranuFlo recall will be included on the Firm’s new website.

Individuals who are eligible to file a lawsuit against Fresenius Medical Care, the manufacturer of these acid concentrates, may have experienced heart problems within 72 hours of a dialysis treatment that used GranuFlo or NaturaLyte. According to court documents filed in November, almost 400 cases alleging injuries caused by these medications are now pending in a federal litigation underway in the U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“With this new website, individuals who may have been injured as a result of GranuFlo or NaturaLyte will be connected with the resources they need to file a claim against Fresenius,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including GranuFlo and NaturaLyte. The Firm is currently offering free and confidential case evaluations to anyone who may have sustained the life-threatening heart problems associated with either of these medications.

GranuFlo Lawsuits
A recent update from the U.S. Judicial Panel on Multidistrict Litigation (JPML) indicates that 393 NaturaLyte and GranuFlo lawsuits were pending in the federal Massachusetts proceeding as of November 18th, 2013. Cases filed in this litigation, which held its most recent status conferen
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes New Plaintiff Filing in Federal Ethicon Vaginal Mesh Litigation
2. DePuy ASR Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal DePuy ASR Hip Recall Litigation
3. Ethicon Transvaginal Mesh Lawsuits Mount, as Bernstein Liebhard LLP Notes More than 16,000 Filings in Federal, State Litigations
4. DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Order Delaying Consideration of Remand Motions in Federal Pinnacle Hip Litigation
5. As Pradaxa Lawsuits Move Forward, Bernstein Liebhard LLP Notes Manufacturer is Working on Possible Antidote for Internal Bleeding Caused by the Blood-Thinner
6. DePuy Pinnacle Lawsuit Claims Mount, as Bernstein Liebhard LLP Notes Nearly 6,000 Filings in Federal Pinnacle Hip Litigation
7. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
8. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of December Case Management Conference in New Jersey Stryker Hip Recall Litigation
9. Transvaginal Mesh Lawsuits Progress, As Bernstein Liebhard LLP Notes Scheduling of Motions Hearing in Federal Vaginal Mesh Litigations
10. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Conference in New Jersey Vaginal Mesh Litigations
11. Federal GranuFlo Lawsuits Progress, as Bernstein Liebhard LLP Notes Issuance of New Case Management Order in GranuFo Recall Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... world-leading provider of scientific, technical and medical information ... a position statement by the European Menopause and ... on the topic of breast cancer screening. ... in women, with slightly more than ten percent ... is a well-established method to detect breast cancer. ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In ... Services, Inc.’s Drug Benefit News (DBN) continues to ... reported in its Aug. 8 issue , CVS ... exclusion lists for 2015 each cut more drugs ... much savings these exclusions are likely to achieve. ...
(Date:9/17/2014)... 17, 2014 In a continuing effort ... Nile virus threats, Mosquito Shield of the South Shore ... with the Hanover Youth Athletic Association to treat area ... daily practices going until dusk, prime mosquito feeding time, ... athletes, coaches, and parents involved in outdoor athletic activities. ...
(Date:9/17/2014)... 17, 2014 According to new ... the leading global authority in medical device market ... regeneration market is expected to exceed $3.7 ... breast reconstruction, hernia repair, dural repair, vaginal slings, ... dental soft tissue regeneration. , Approximately 300,000 ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3
... March 10 Speaker Nancy Pelosi and Majority Whip James E. Clyburn held a photo opportunity this afternoon with representatives from the National Association of Public ... ... ... ...
... uncovered a mechanism for resistance to paclitaxel in ovarian ... chemotherapy resistance. Mohamed K. Hassan, Ph.D., a ... research as a collaborative study with his colleagues when ... in Egypt. Results of this study were presented at ...
... treating tumors with extreme heat or moderate heat may ... presented at the second AACR Dead Sea International Conference ... the Clinic, held March 7-10, 2010. "Low ... in curing both malignant and benign tumors using minimally ...
... , March 10 Omega Protein Corporation (NYSE: OME ), the nation,s leading producer of Omega-3 fish oil and specialty fish meal ... with net income of $12.6 million ( $0.69 per share) for the year ended December 31, 2008 . , ... ... ...
... 10 International Merchant Advisors, Inc. (PK: IMAI) ... announced today that the company is preparing to ... Organic Science, Inc.  Organic Science, Inc. is intended to become ... and is focused on the implementation of Organic,s  plans for ...
... March 10 As part of its continued focus on developing programs designed to meet employers, needs, Regence has acquired the assets of Kinetix Living Corp., ... ... , ... ...
Cached Medicine News:Health News:Pelosi Remarks at Photo Opportunity with the National Association of Public Hospitals 2Health News:Omega Protein Reports 2009 Results 2Health News:Omega Protein Reports 2009 Results 3Health News:Omega Protein Reports 2009 Results 4Health News:Omega Protein Reports 2009 Results 5Health News:Omega Protein Reports 2009 Results 6Health News:Omega Protein Reports 2009 Results 7Health News:Omega Protein Reports 2009 Results 8Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 2Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 3Health News:Regence Invests in Kinetix Living Corp. 2Health News:Regence Invests in Kinetix Living Corp. 3
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
... G rowth factor enhances ... stem cells , , BOSTON, July ... Boston have now laid the groundwork for regenerating heart tissue after a heart ... In the July 24 issue of Cell , they show that a ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
... The ThromCat™ System is the first thrombectomy ... strength and simplicity for the full range ... Heliflex™ technology, the new ThromCat™ System flushes, ... of 700 mmHg and incorporates advanced vessel-wall ...
... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
... Tendril ST leads are ... leads, designed to bring ... and flexibility to you ... pre-formed "J leads are ...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
Medicine Products: